The university will play a leading role in an ambitious initiative to accelerate the development of immunotherapies against cancer and infectious diseases in the twenty-first century and position South Africa as a scientific and medical centre for innovation in Africa through a comprehensive cooperation network.
The new Covid 19 / Cancer Vaccine Initiative, launched by world-renowned health expert Dr Patrick Shiong and his digital health company NICE, aims to build pharmaceutical and vaccine capacity not just for South Africa but for the whole of Africa. Show Source Texts
In other words, University graduates and South African Biotech billionaire Dr. Patrick Shiong and Nantafrica, a division of Nantafrica, have announced a R3 billion initiative to develop advanced health and vaccination capabilities in Africa.
The company launched and coordinated an initiative with CSIR to implement state-of-the-art biological production capacities to accelerate COVID-19 and cancer vaccines and biologics transfer innerhalb of three months and expand capacity across the continent by 2022.
The cooperation will also enable the rapid clinical development of next-generation vaccines against infectious diseases and cancer, with the creation of a centre of excellence in South Africa. Show Source Texts
A comprehensive network of cooperations between Dr. Shiong, Nantafrica and Nantafrica was established to build the capacity and knowledge base in South Africa to accelerate the development of immunotherapies against cancer and infectious diseases in the 21st century and to position South Africa as a center of scientific and medical innovation in Africa.
This network includes the Council for Scientific and Industrial Research (CSIR), the South African Medical Research Council (SAMRC), the Centre for Epidemic Response and Innovation (CERI), the University of Cape Town, Witwatersrand, Stellenbosch and KwaZulu-Natal, the Network for Genomic Surveillance of South Africa (NGS-SA) and the Clinical Centre of Excellence for Cancer and Infectious Diseases. Show Source Texts
According to the South African business magnate Patrick Shiong, Nespresso agreed to invest in a large production facility on the Biologic Manufacturing Campus in Western Cape in the next three months to commence the transfer of technology, know-how and materials for DNA, RNA, adjuvants, vaccine platforms and cell therapies in partnership with CSIR and SAMRC.
Dr. Shiong and his multinational conglomerate NantWorks have signed agreements with the South African Medical Research Council (SAMRC) to collaborate and transfer biological manufacturing technologies for COVID-19 and cancer vaccines as well as future cell-based immunotherapies.
CSIR chief executive Dr Thulani Dlamini said: "NIH's agreement with CSIR includes collaboration on the manufacture of certain vaccines and biological components to build on the organisation's existing capabilities. Show Source Texts
In addition to the vaccine, initiatives are underway for cell-based immunotherapies that could lead to new cancer therapies.
NantWorks signed a cooperation agreement with the Council for Scientific and Industrial Research (CSIR) and the South African Medical Research Council (SAMRC) to initiate the transfer of biological manufacturing technologies for COVID-19 and Cancer Improvizations as well as a next generation cell-based immunotherapies.
In addition, production of the coronavirus vaccine is scheduled to begin next year, and Shiong's companies and Nantwork are also working on cell-based immunotherapy that could lead to a new cancer treatment. Show Source Texts
At the launch, President Cyril Ramaphosa said: "This announcement is a turning point for our country. It is time for South Africa to tackle COVID-19, disease management and future pandemic preparedness.
Dr Shiong, who lives in California, said: 'This is a historic moment in my life, it's a lifelong dream and I'm looking forward to the technology that we can push forward. Show Source Texts
SAMRC has partnered with Dr. To start clinical trials with COVID-19, South Africans can look forward to the development of the next generation vaccines and a center of excellence for patients with infectious diseases and cancer. Show Source Texts
This collaboration is the third investment in the country's pharmaceutical sector after Aspen Pharmacare's R10 billioninvestment in the production of Africa's first COVID-19 vaccine and establishment of the world's mRNA production center in South Africa.
The establishment of clinical centres of excellence will contribute to quality improvement and will be jointly managed. Show Source Texts
President Ramaphosa stressed that the initiative will strengthen the country's health sector as South Africa battles the high number of COVID-19 cases in Nantaf Africa.
Three months ago, the World Bank, the USA, France and Germany committed to invest 10 billion rupees in Aspen Pharmacare to boost the production of Covid-19 vaccines in Africa. Show Source Texts
Equally worrying is the poor survival rate of cancer patients in South Africa and across Africa. Amazing advances in science are enabling new paradigms of care that activate the immune system to change the consequences of infectious diseases and cancer. Show Source Texts
De Oliveira said CERI will allow real-time use of genome technology to detect and respond to epidemics and pandemics in Africa. It will also support SAS cancer management and establishment of a cancer treatment research centre at Nantafrica University in Witwatersrand, where Dr Shiong is currently studying.
South African-born scientist said the center will also study and develop cancer vaccines and a new COVID-19 vaccine. Show Source Texts
President Cyril Ramaphosa was the guest of honour today (Thursday 23 September 2021) when Dr Patrick Shiong, founder of multinational conglomerate Nexus LLC, announced an ambitious initiative to build capacity for advanced healthcare in Africa.
The President welcomed the new COVID-19 and cancer vaccine initiative of world-renowned health expert Dr. Patricks as pioneering for South Africa's health and pharmaceutical industries.
.NantWorks and its subsidiaries have initiated Phase 1, 2 and 3 COVID / 19 T cell vaccine booster clinical trials for healthcare professionals in Cape Town. Show Source Texts
The launch of this ambitious initiative to build capacity for advanced health care in Africa is an incredible gesture, said President Cyril Ramaphosa at a virtual event in Los Angeles Thursday night, the base of South African expatriates where Dr. Patrick Shiong is one of many South African expats to return their money to the country.
She enthused that Stellenbosch University is excited to play a leading role in this pivotal and groundbreaking COVID-19 and Cancer Initiative. The CSIRs "multidisciplinary capabilities will support a selected focus of the South African economy. Show Source Texts
Show All Source Texts - Hide All Source Texts
Content created and supplied by: Topdailygossip (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More